Rebecca A. Shatsky, MD

Articles

Navigating Treatment Selection for HER2-Low and -Ultralow Metastatic Breast Cancer

July 14th 2025

Panelists discuss how treatment options for HER2-low and HER2-ultralow metastatic breast cancer include trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan, with sequencing becoming a key consideration.

Balancing Efficacy and Safety of ADCs in HER2– Metastatic Breast Cancer

July 14th 2025

Panelists discuss how to manage toxicities associated with datopotamab deruxtecan, particularly ocular toxicity and stomatitis, using prophylactic measures such as steroid mouthwash and eye drops.

Evolving ADC Strategies in HER2– mBC: TROPION-Breast01 and Real-World Data From ASCO 2025

July 7th 2025

Panelists discuss how datopotamab deruxtecan from the TROPHY-PD-01 trial compares with sacituzumab govitecan, highlighting different toxicity profiles and the challenge of sequencing multiple antibody-drug conjugates (ADCs) with the same TROP2 payload.

TROPiCS-02 Trial: Sacituzumab Govitecan in HR+/HER2– Breast Cancer

July 7th 2025

Panelists discuss how the TROPiCS-02 trial established sacituzumab govitecan for hormone receptor–positive, HER2-negative metastatic breast cancer and how it influences sequencing decisions with other antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan.

When to Introduce ADCs in HR+/HER2– mBC

June 30th 2025

Panelists discuss how they decide when to transition from endocrine-based therapies to antibody-drug conjugates, considering factors such as endocrine sensitivity, disease burden, and pace of progression.

Optimizing Treatment Selection and Sequencing in HR+/HER2– mBC

June 30th 2025

Panelists discuss how to approach decision-making among PI3K/AKT pathway inhibitors (capivasertib, alpelisib, everolimus) based on mutation status, toxicity profiles, and dosing schedules in the second-line setting.

Efficacy and Safety of Next-Generation Oral SERDs for HR+/HER2– mBC

June 23rd 2025

Panelists discuss how upcoming oral selective estrogen receptor degraders (SERDs; eg, camasertinib, imlunestrant, and giredestrant) are showing efficacy primarily in populations with ESR1 mutations and are all well-tolerated oral agents that will likely receive approvals.

The Role of Elacestrant in the Treatment of ER+/HER2– mBC

June 23rd 2025

Panelists discuss how elacestrant from the EMERALD trial is being incorporated into practice based on ESR1 mutation status and duration of prior CDK4/6 inhibitor therapy, with combination approaches being explored in the ELEVATE trial.

Camizestrant in HR+/HER2– mBC: Emerging Data From the SERENA-6 Trial

June 16th 2025

Panelists discuss how the SERENA-6 trial design uses circulating tumor DNA (ctDNA) monitoring to detect ESR1 mutations and switch patients from aromatase inhibitors to oral selective estrogen receptor degraders (SERDs) such as camasertinib while continuing CDK4/6 inhibitors.

Biomarker Testing Strategies in Metastatic Breast Cancer

June 16th 2025

Panelists discuss how they will review the latest updates in hormone receptor–positive, HER2-negative, and HER2-low metastatic breast cancer, focusing on oral selective estrogen receptor degraders (SERDs), targeted therapies, and antibody-drug conjugates presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

SABCS 2024: Promising Studies in HR+ and HER2– mBC and Early-Stage TNBC

February 17th 2025

Panelists discuss the most exciting data and studies presented at the San Antonio Breast Cancer Symposium (SABCS) that show promise for improving outcomes in both HR-positive (HR+) and HER2-negative (HER2–) metastatic breast cancer and early-stage triple-negative breast cancer (TNBC), highlighting how precision medicine has enhanced outcomes and the overall patient experience.

Sequencing Sections for Patients With Both BRCA Mutations and Early-Stage TNBC

February 17th 2025

Panelists discuss factors influencing the decision to continue adjuvant immunotherapy for patients achieving pathologic complete response (pCR) with pembrolizumab-containing therapy, weighing the benefits against risks and considering the role of biomarkers. They also explore sequencing decisions for patients with both BRCA mutations and early-stage triple-negative breast cancer (TNBC), focusing on the prioritization of PARP inhibition versus immunotherapy and situations where both may be recommended. Additionally, they discuss approaches to monitoring and managing immune-related adverse events, including baseline screening and ongoing management protocols.

KN-522: Clinical Implications and Insights Into Clinical Practice

February 10th 2025

Panelists highlight the KN-522 study and discuss how updated KEYNOTE-522 data influence their selection of patients for pembrolizumab-containing regimens, focusing on factors that guide the decision to recommend immunotherapy and how to approach patients with borderline indications.

Role of PARP Inhibitors in Somatic BRCA Mutations and Data Update for PARP Inhibitors

February 10th 2025

Panelists discuss how recent data inform their approach to PARP inhibitor use in the metastatic setting, exploring the role of PARP inhibition for somatic BRCA mutations and strategies for managing PALB2 and other homologous recombination deficiency mutations.

OlympiA: Data Updates From SABCS 2024

February 3rd 2025

Panelists review the recent OlympiA data presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) and discuss how the findings influence their approach to sequencing adjuvant olaparib with other systemic therapies for breast cancer patients.

BRCA Testing in Early-Stage and Metastatic Breast Cancer

February 3rd 2025

Panelists discuss their approach to BRCA testing in early-stage versus metastatic breast cancer patients, highlighting the 2024 American Society of Clinical Oncology (ASCO) guidelines for germline testing and exploring which patients are not tested for BRCA, as well as how they differentiate between germline and somatic testing approaches.

Adjuvant CDK 4/6 Inhibitors for High-Risk HR+/HER2– Early Breast Cancer: Toxicity Management and Real-World Data

January 27th 2025

Panelists discuss the factors influencing the choice between abemaciclib and ribociclib for adjuvant CDK4/6 inhibitor therapy, including patient characteristics and safety profiles, and explore strategies for toxicity management, maintaining dose intensity, and addressing adherence or toxicity challenges in real-world clinical practice.

NATALEE and monarchE: Clinical Data Review and Insights Into Treating High-Risk HR+/HER2_ Early-Stage Breast Cancer

January 27th 2025

Panelists discuss the recent data from the NATALEE and monarchE studies, focusing on adjuvant CDK4/6 inhibitor selection for high-risk HR-positive/HER2-negative (HR+/HER2–) early breast cancer patients, and explore how to interpret the different efficacy signals, particularly the early curve separation observed in monarchE versus NATALEE.